Opinion

Video

The Evolution of Imaging Techniques in Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Brian Chapin, MD

A panel of expert oncologists in prostate cancer give an overview of the evolution of imaging techniques used for patients with prostate cancer.

Current Time 0:00
Duration 6:22
Loaded: 0%
Stream Type LIVE
Remaining Time 6:22
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Ruben Olivares, MD, answers a question during a Zoom video interview
    Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
    Post-RP incontinence: Low procedure rates examined
    Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
    Data link incontinence severity to post-radical prostatectomy care
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
    Expert discusses differentiating prostate cancer from age-related issues
    Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
    Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
    Related Content
    Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC
    July 2nd 2025

    Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

    Hannah Clarke
    The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    FDA updates in urology: June 2025
    July 1st 2025

    FDA updates in urology: June 2025

    Hannah Clarke
    A recap of the FDA submissions and regulatory decisions in urology from June 2025.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Conceptual image for viral ethiology of prostate cancer. 3D illustration showing Human Papilloma Viruses HPV infecting prostate gland which develops cancerous tumor | Image Credit: © Dr_Microbe - stock.adobe.com
    June 27th 2025

    Biden’s prostate cancer diagnosis underscores importance of screening, awareness

    Hannah Clarke
    The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.
    Colorful DNA molecule. Concept image of a structure of the genetic code. | Image Credit: © ktsdesign - stock.adobe.com
    June 26th 2025

    Genomic test can predict resistance to chemotherapy in prostate cancer

    Hannah Clarke
    The test utilizes chromosomal instability signatures to predict resistance to taxane-based chemotherapy in metastatic prostate cancer.
    © 2025 MJH Life Sciences

    All rights reserved.